Research Paper Volume 15, Issue 11 pp 4963—4985
FDX1 serves as a prognostic biomarker and promotes glioma progression by regulating the immune response
Figure 2. Association between FDX1 and prognosis in glioma. (A–F) Comparison of FDX1 expression levels based on different tumor types, histology, grade, IDH mutation status, 1p19q codeletion status, and chemotherapy status. (G, H) Kaplan-Meier curves from TCGA data indicate that high FDX1 expression is associated with poor prognosis. (I) Univariate and multivariate Cox regression performed using TCGA data show FDX1 to be an independent prognostic factor in glioma. (J, K) Kaplan-Meier curves from CGGA data show high FDX1 expression to be associated with poor prognosis. (L) Univariate and multivariate Cox regression using CGGA data indicate FDX1 to be an independent prognostic factor in glioma.